Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure.

Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Otsu, Japan.
Journal of the American College of Cardiology (Impact Factor: 15.34). 03/2006; 47(3):582-6. DOI: 10.1016/j.jacc.2005.10.038
Source: PubMed

ABSTRACT This study sought to evaluate the relationship between brain natriuretic peptide (BNP), renal function, and the severity of congestive heart failure (CHF).
Both BNP and renal function are prognostic predictors in CHF patients.
We measured the plasma BNP level in the aortic root and coronary sinus in 366 consecutive patients with CHF. Estimated glomerular filtration rate (eGFR) by the Cockcroft-Gault equation was used as an indicator of renal function.
By stepwise multivariate analyses, hemodynamic parameters such as left ventricular ejection fraction (LVEF) and left ventricular end-diastolic pressure (LVEDP) but not eGFR were independent predictors of a transcardiac increase (coronary sinus-aortic root) in BNP. Regarding the plasma level of BNP in the aortic root, not only LVEF (p < 0.0001) and LVEDP (p < 0.0001) but also eGFR (p < 0.0001) were independent predictors. Patients were divided into two groups, patients with an eGFR > or =60 ml/min (group 1, n = 229) and patients with an eGFR <60 ml/min (group 2, n = 137). There was no difference in LVEF, LVEDP, or the transcardiac gradient of BNP between the two groups, but the plasma level of BNP in the aortic root was approximately two-fold greater in group 2 than in the group 1.
These findings suggest that decreased clearance from the kidney contributes to the elevated BNP in CHF patients with renal dysfunction, especially in patients with an eGFR <60 ml/min.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimThe purpose in the present study was to compare prognostic risk factors between older and younger chronic heart failure (CHF) patients.Methods We examined 598 consecutive CHF patients (476 men and 122 women, mean age 61.4 ± 14.3 years) who underwent cardiopulmonary exercise testing, echocardiography and blood examination. We divided the 598 patients into two groups: the elderly group (age ≥75 years, n = 123) and the young group (age <75, n = 475). We compared blood testing data, exercise capacity, cardiac function and prognosis between the two groups. Patients were followed up (median 782 days) to register cardiac deaths or rehospitalization as a result of worsening heart failure.ResultsPatients in the elderly group were associated with higher frequencies of atrial fibrillation and diuretic use than those in the young group. Patients in the elderly group had lower hemoglobin concentration, more impaired renal function, higher plasma B-type natriuretic peptide (BNP) levels, smaller left ventricular volume, longer deceleration time of early mitral wave and lower exercise capacity than those in the young group. There were 199 cardiac events during follow-up periods. As expected, Kaplan–Meier analysis showed that patients in the elderly group had higher cardiac event rates than those in the young group. In the young group, multivariable Cox hazard analysis showed that hemoglobin concentration, log BNP and peak VO2 were independent predictors related to cardiac events. In contrast, in the elderly group, estimated glomerular filtration rate, atrial fibrillation and peak VO2 were independent factors to predict adverse clinical outcomes.Conclusions Prognostic factors were different between the elderly and young patients in CHF. Geriatr Gerontol Int 2014; ●●: ●●–●●.
    Geriatrics & Gerontology International 05/2014; · 1.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Myxomatous mitral valve disease causing mitral regurgitation (MR) is a common cause of heart failure in dogs. However, many aspects of pathophysiology affecting diagnostic measurements are poorly defined. The objective of this study was to add to the knowledge of different pathophysiological processes affecting measures used. Focus was put on plasma parameters, including N-terminal pro A-type natriuretic peptide (NT-proANP) and nitric oxide (NO), and first pass radionuclide angiocardiography to evaluate heart pump function and possible right sided heart enlargement associated with pulmonary hypertension. Echocardiography and thoracic radiographs were used as reference methods. Results. In normal dogs both NT-proANP (P=0.002) and NO (P=0.01) increased with age. Plasma NT-proANP concentrations for dogs under 5.9 years of age were lower than for dogs older than 5.9 years (inter quartile range 190–270 pmol/l vs. 307–530, respectively), with no overlap between groups. This discrimination was not seen for NO. In healthy dogs heart rate normalized blood pulmonary transit time (nPTT) was 4.4±0.6, dogs with asymptomatic MR 6.3±1.6, and dogs with CHF 11.8±3.4 (P<0.001). The size of the right heart chambers increased only late in MR. Pulmonary blood volume (PBV) was associated with nPTT (R2=0.85, P<0.0001) but not with forward stroke volume. Increase in PBV appeared late in the phase before CHF. The hazard ratio for NT-proANP was 1.21 (per 100 pmol/l; P<0.0002). The median time to failure was 11 months for dogs with NT-proANP concentrations >1000 pmol/l and 54 months for dogs with concentrations ≤1000 pmol/l (P<0.0001). Dogs that developed CHF had a lower mean plasma level of NO than dogs not reaching CHF (mean 23 vs. 28 µmol/l (as nitrite), P=0.016). Increased heart rate (>130 beats/min, P<0.001) and heart murmur (3-6/6 vs. 1-2/6, P<0.001) increased risk. Conclusions. Specific normal values for natriuretic peptides should be established for different age groups of dogs. Heart rate, murmur and NT-proANP can be used to predict risk of and time to heart failure in dogs with MR. Heart rate normalized PTT (nPTT) is a robust measure of heart pump function in MR. Both nPTT and pulmonary blood volume increase before onset of CHF. Apparent right-sided heart enlargement on radiographs is due to them being displaced by left heart chambers as they enlarge only in severe MR.
    11/2013, Degree: PhD
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is increasing interest in utilising novel markers of cardiovascular disease risk in patients with chronic heart failure (HF). Recently, it was shown that alpha-1-antichymotrypsin (ACT), an acute-phase protein and major inhibitor of cathpesin G, plays a role in the pathophysiology of HF and may serve as a marker for myocardial distress.
    Netherlands heart journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 08/2014; 22(9). · 2.26 Impact Factor

Full-text (2 Sources)

Available from
May 29, 2014